2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-161753
    CFTR potentiator 1 98%
    CFTR potentiator 1 (I1421) is a potent CFTR potentiator with an EC50 value of 64 nM. CFTR potentiator 1 allosterically activates a wide range of CF-causing mutants, such as ΔF508 and G551D CFTR.
    CFTR potentiator 1
  • HY-161757
    Anti-inflammatory agent 86 98%
    Anti-inflammatory agent 86 is a Chrysin (HY-14589) derivative with anti-inflammatory effects. Anti-inflammatory agent 86 inhibits monocyte adhesion to colon epithelium induced by TNF-α, with an IC50 of 4.71 μM. Anti-inflammatory agent 86 has the potential for the inflammatory bowel disease (IBD) research.
    Anti-inflammatory agent 86
  • HY-161778
    ZG-126 3049802-32-3 98%
    ZG-126 is an agonist for vitamin D receptor (VDR) and an inhibitor for histone deacetylase (HDAC) (IC50=0.63-67.6 μM). ZG-126 exhibits cytotoxicity in cancer cells MDA-MB-231 and 4T1. ZG-126 exhibits antitumor and anti-metastatic efficacy against melanoma and triple-negative breast cancer (TNBC) in mouse models. ZG-126 also exhibits anti-inflammatory activity, through the reduction of macrophage infiltration and immunosuppressive M2-polarization.
    ZG-126
  • HY-161815
    Anti-inflammatory agent 89 98%
    Anti-inflammatory agent 89 is a multi-target glucocorticoid-isothiocyanate hybrid with anti-inflammatory activity. Anti-inflammatory agent 89 releases hydrogen sulfide via its isothiocyanate group, inhibits antigen-induced mast cell degranulation, alleviates pulmonary inflammation, and suppresses bronchial hyperresponsiveness and airway fibrosis. Anti-inflammatory agent 89 can be used in asthma research.
    Anti-inflammatory agent 89
  • HY-161818
    LLW-018 3049369-11-8 98%
    LLW-018 is a potent PD-1/PD-L1 inhibitor with an IC50 value of 2.61 nM. LLW-018 can interrupt PD-1/PD-L1 interaction with an IC50 value of 0.88 μM by cell-based PD-1/PD-L1 blockade bioassays. LLW-018 has the potential for immunotherapy research.
    LLW-018
  • HY-161833
    HSP90-IN-31 2117645-10-8 98%
    HSP90-IN-31 (compound Be01) causes reduction of CD80 and CD86 expression on dendritic cells (DCs). HSP90-IN-31 decreases the production of pro-inflammatory cytokines (IL-6, TNF-α, and IL-1β) in BMDC and peritoneal macrophages stimulated by LPS (HY-D1056). Under the delayed-type hypersensitivity (DTH) mice model, HSP90-IN-31 reduces ear swelling and pro-inflammatory cytokines in the spleen.
    HSP90-IN-31
  • HY-161835
    SR140333B 155418-06-7 98%
    SR140333B is a selective NK1 receptor inhibitor that can reduce LPS-induced fever and mitigate LPS (HY-D1056)-induced changes in brain tissue in rats.
    SR140333B
  • HY-161843
    Necroptosis-IN-4 98%
    Necroptosis-IN-4, a potent necroptosis inhibitor, is a RIP kinase 1 (RIPK1) inhibitor. Necroptosis-IN-4 has no inhibitory activity against RIPK3 and weak inhibitory activity against VEGFR1/2 and PDGFR-α.
    Necroptosis-IN-4
  • HY-161862
    COX-2-IN-44 98%
    COX-2-IN-44 is a potent and orally active COX-2 inhibitor with IC50 values of 0.18,1.14 µM for COX-2, COX-1, respectively. COX-2-IN-44 shows anti-inflammatory activity.
    COX-2-IN-44
  • HY-161864
    STAT3-IN-29 2256751-16-1 98%
    STAT3-IN-29 (Compound B20) is an inhibitor for STAT3. STAT3-IN-29 inhibits the proliferation of HaCaT cell with IC50 of 0.09 µM, ameliorates the IMQ-induced psoriasis in mouse models.
    STAT3-IN-29
  • HY-161892
    FABP4-IN-4 98%
    FABP4-IN-4 (Compound 30) is an orally active inhibitor for FABP, with IC50 of 1.18 μM for FABP 1. FABP4-IN-4 improves the glucose tolerance, reduces the level of blood glucose, plasma lipids and hepatic inflammatory factors, attenuates hepatic steatosis, and exhibits anti-inflammatory effects in mouse diet-induced obesity models.
    FABP4-IN-4
  • HY-161894
    CFTR corrector 13 98%
    CFTR corrector 13 (SVQ18) is a cystic fibrosis transmembrane conductance regulator (CFTR) corrector (EC50=3.14 μM). CFTR corrector 13 enhances the function of CFTR channels, especially when used in combination with Lumacaftor (HY-13262), it can produce a dose-dependent increase in CFTR function. CFTR corrector 13 can be used in the study of cystic fibrosis (CF) and other CFTR-related diseases.
    CFTR corrector 13
  • HY-161911
    Necroptosis-IN-5 98%
    Necroptosis-IN-5 (Compound 26) is an orally active necroptosis inhibitor. Necroptosis-IN-5 also exhibits potent inhibitory activity against receptor-interacting protein kinase 1 (RIPK1). Necroptosis-IN-5 can be used to study necroptosis-related inflammatory diseases, neurodegenerative diseases, and cancers.
    Necroptosis-IN-5
  • HY-161917
    HPK1-IN-49 2845144-97-8 98%
    HPK1-IN-49 (Compound I-4) is an inhibitor for hematopoietic progenitor kinase 1 (HPK1) with an IC50 >100 nM.
    HPK1-IN-49
  • HY-161925
    sTGFBR3 antagonist 1 98%
    sTGFBR3 antagonist 1 (Compound p24) is an antagonist for soluble transforming growth factor beta receptor 3 (sTGFBR3), thus activates TGF-β signaling pathway, and inhibits IκBα/NF-κB signaling pathway. sTGFBR3 antagonist 1 inhibits NO-release in LPS (HY-D1056) -induced BV2 cells with an IC50 of 0.52 μM. sTGFBR3 antagonist 1 exhibits anti-inflammatory and neuroprotective activities with blood brain barrier (BBB) permeability. sTGFBR3 antagonist 1 can be used in Alzheimer’s Disease research.
    sTGFBR3 antagonist 1
  • HY-161936
    Z21115 2958668-54-5 98%
    Z21115 is an orally active inhibitor for phosphodiesterase 4 (PDE4), that inhibits PDE4D7 with IC50 of 10.5 nM. Z21115 inhibits Lipopolysaccharide (HY-D1056)-induced expression of IL-6, TNF-α and iNOS. Z21115 exhibits anti-inflammatory activity in DSS (HY-116282)-induced mouse colitis models without significant toxicity (1 g/kg).
    Z21115
  • HY-161976
    ACC1-IN-2 3027705-67-2 98%
    ACC1-IN-2 (Compound 16) is an ACC1 inhibitor with an IC50 of 7.3 nM. ACC1-IN-2 can be used in the study of acne.
    ACC1-IN-2
  • HY-161992
    Nrf2 activator-11 3069351-39-6 98%
    Nrf2 activator-11 (compound M11) is a Nrf2 activator with blood-brain permeability. Nrf2 activator-11 has anti-oxidation, anti-inflammation, anti-ferroptosis and anti-apoptosis. Nrf2 activator-11 can be used to study cerebral  ischemia-reperfusion (CI/R) injury models.
    Nrf2 activator-11
  • HY-161994
    COX-2-IN-47 2043670-02-4 98%
    COX-2-IN-47 (compound 6c ) is a selective COX-2 inhibitor with IC50 value of 0.03 μM. COX-2-IN-47 has antiedema activity.
    COX-2-IN-47
  • HY-161996
    IDO1-IN-25 2841467-86-3 98%
    IDO1-IN-25 is a dual inhibitor of IDO1/TDO2, with IC50 values of 0.17 μM and 3.2 μM, respectively. IDO1-IN-25 can effectively inhibit the production of NO in RAW264.7 cells stimulated by lipopolysaccharide (LPS). IDO1-IN-25 can exert anti-inflammatory effects in a mouse ear edema acute inflammation model induced by croton oil.
    IDO1-IN-25
Cat. No. Product Name / Synonyms Application Reactivity